Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Enfortumab Vedotin +/- Pembro in Pts Who Are Cisplatin-Ineligible With Previously Untreated Locally Advanced or mUC - Additional 3-Month Follow-Up on Cohort K Data"
Comments 0
Login to view comments.
Click here to Login
